ADB-PINACA

ADB-PINACA is a synthetic cannabinoid that has recently emerged in the designer drug market. It is part of a group of novel psychoactive substances (NPS) that are designed to mimic the effects of traditional cannabis. ADB-PINACA was first identified in 2013 and has since been found in various herbal blends marketed as "legal highs" or "herbal incense." Its chemical name is N-[(2S)-1-amino-3-methyl-1-oxobutan-2-yl]-1-pentyl-1H-indazole-3-carboxamide, indicating its structure as a derivative of indazole carboxamide.
Chemistry[edit]
ADB-PINACA is a synthetic cannabinoid that belongs to the indazole-3-carboxamide family. Its molecular formula is C₁₉H₂₆N₄O₂. This compound is a potent agonist of the CB₁ receptor, with a significantly higher affinity than THC, the primary psychoactive compound found in natural cannabis. The presence of the N-[(2S)-1-amino-3-methyl-1-oxobutan-2-yl] group in its structure is believed to contribute to its high potency.
Pharmacology[edit]
The pharmacological action of ADB-PINACA is primarily through its activity as an agonist at the cannabinoid receptors, CB₁ and CB₂. Its affinity for these receptors is much higher than that of THC, leading to its potent psychoactive effects. The exact pharmacological profile of ADB-PINACA, including its efficacy and potency at these receptors, is still under investigation. However, its strong binding to the CB₁ receptor is associated with psychoactive effects that mimic those of Δ⁹-THC, albeit with potentially greater intensity and duration.
Effects[edit]
Users of ADB-PINACA report effects similar to those of natural cannabis, including euphoria, relaxation, altered perception, and in some cases, anxiety and paranoia. However, due to its higher potency, the risk of experiencing adverse effects, including severe toxicity and life-threatening conditions, is significantly increased. Cases of acute intoxication and hospitalization have been reported, highlighting the unpredictable and potentially dangerous nature of this synthetic cannabinoid.
Legal Status[edit]
The legal status of ADB-PINACA varies by country and jurisdiction. It has been listed as a controlled substance in several countries, including the United States, where it is classified as a Schedule I substance under the Controlled Substances Act, indicating it has a high potential for abuse, no currently accepted medical use in treatment, and a lack of accepted safety for use under medical supervision. Other countries have enacted similar measures to control the distribution and use of ADB-PINACA and related synthetic cannabinoids.
Health Risks[edit]
The health risks associated with ADB-PINACA are significant, due in part to its high potency and the lack of research on its long-term effects. Acute health risks include tachycardia, hypertension, nausea, vomiting, agitation, hallucinations, and, in severe cases, seizures, acute kidney injury, and death. The unpredictable nature of synthetic cannabinoids, combined with the potential for contamination and variation in chemical composition, further exacerbates these risks.
Conclusion[edit]
ADB-PINACA is a potent synthetic cannabinoid that poses significant health risks to users. Its legal status in many countries reflects growing concern over the safety and potential for abuse of synthetic cannabinoids. Ongoing research is necessary to fully understand the pharmacological, toxicological, and behavioral effects of ADB-PINACA and similar compounds.
Ad. Transform your health with W8MD Weight Loss, Sleep & MedSpa

Tired of being overweight?
Special offer:
Budget GLP-1 weight loss medications
- Semaglutide starting from $29.99/week and up with insurance for visit of $59.99 and up per week self pay.
- Tirzepatide starting from $45.00/week and up (dose dependent) or $69.99/week and up self pay
✔ Same-week appointments, evenings & weekends
Learn more:
- GLP-1 weight loss clinic NYC
- W8MD's NYC medical weight loss
- W8MD Philadelphia GLP-1 shots
- Philadelphia GLP-1 injections
- Affordable GLP-1 shots NYC
|
WikiMD Medical Encyclopedia |
Medical Disclaimer: WikiMD is for informational purposes only and is not a substitute for professional medical advice. Content may be inaccurate or outdated and should not be used for diagnosis or treatment. Always consult your healthcare provider for medical decisions. Verify information with trusted sources such as CDC.gov and NIH.gov. By using this site, you agree that WikiMD is not liable for any outcomes related to its content. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
